01/29/2021

Live-Chat mit Chirurgen am OP-Tisch

Gelungene Premiere: Einschnitte – Einblicke als Online-Workshop (Stuttgart/Tübingen) – Die erste Ausgabe der bekannten Workshop-Reihe „Einschnitte – Einblicke“ im Jahr 2021 fand am vergangenen Mittwoch pandemiebedingt als Online-Veranstaltung statt. Moderiert von Dr. Klaus Eichenberg und Anja Reutt...
01/28/2021

CureVac Announces Pricing of $450 million Follow-on Public Offering of Common Shares

CureVac N.V. (Nasdaq: CVAC) (“CureVac” or the “Company”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonuc...
01/28/2021

Bioökonomie 360°: Das Brot der Zukunft

Stabile Qualität trotz Klimawandel, weniger Dünger, effiziente Bäckereien, gesunde Ernährung, Abfallverwertung: Bioökonomie interdisziplinär an der Universität Hohenheim am Beispiel Brot

01/28/2021

CureVac kündigt Kapitalerhöhung von 450 Millionen US-Dollar an

CureVac N.V. (Nasdaq: CVAC) („CureVac“ oder das „Unternehmen“), ein globales biopharmazeutisches Unternehmen, das in klinischen Studien eine neue Klasse von transformativen Medikamenten auf der Basis ...
01/27/2021

Insilico announces the release of the Insilico Selector for accurate selection of high-performing cell clones using micro-scale data

Insilico Biotechnology AG announces the release of its new software product, the Insilico Selector. The revolutionary product allows for accurate prediction of clone perf...
01/27/2021

Insilico announces the release of the Insilico Selector for accurate selection of high-performing cell clones using micro-scale data

Insilico Biotechnology AG announces the release of its new software product, the Insilico Selector. The revolutionary product allows for accurate prediction of clone perf...
01/27/2021

OTSC® in first-line treatment of NVUGIB: RCT shows significant benefits of OTSC in rates of rebleeding, severe complications and blood transfusions

53 patients with NVUGIB were randomized to OTSC hemostasis or standard endoscopic treatment. Rebleeding occurred in 4 % in OTSC group vs 28.6 % in standard group (p = 0.0...
01/27/2021

OTSC® in first-line treatment of NVUGIB: RCT shows significant benefits of OTSC in rates of rebleeding, severe complications and blood transfusions

53 patients with NVUGIB were randomized to OTSC hemostasis or standard endoscopic treatment. Rebleeding occurred in 4 % in OTSC group vs 28.6 % in standard group (p = 0.0...